Barcelona Clinical Coordinating Center (BCCC), the lead non-profit contract research
organization (CRO) coordinating patient recruitment and clinical operations, announces the
completion of patient enrollment in the ANGIODAPT-01 trial, a randomized controlled study
evaluating an abbreviated dual antiplatelet therapy (DAPT) regimen following drug-eluting
stent implantation. The trial has been sponsored by iVascular, a company developing
innovative advanced medical devices and therapies for the treatment of disorders of the
cardiovascular system.
ANGIODAPT-01 was designed to evaluate the clinical outcomes of the iVascular Angiolite
coronary stent (compared to another commercially available stent) and determine the
safety and efficacy of an abbreviated vs. standard dual antiplatelet therapy after stent
implantation.
A total of 2312 patients were enrolled across 38 investigational sites in Spain, France and
Belgium. Completion of recruitment represents a major milestone and reflects strong
collaboration among participating investigators and study partners. This study is led by Dr.
Manel Sabaté, from Hospital Bellvitge (Barcelona, Spain)..
“Completion of patient recruitment in this study represents a notable milestone and indicate
the team’s commitment at BCCC” said Xavier Luria Executive Director of Barcelona Clinical
Coordinating Center.
The completion of recruitment represents an important step toward generating robust
clinical evidence to inform DAPT strategies after coronary stent implantation.
About Barcelona Clinical Coordinating Center (BCCC).
Barcelona Clinical Coordinating Center is a non-profit CRO specializing in the coordination
and management of clinical research projects, providing expertise in trial design, site
management, data coordination, as well as regulatory and statistical consulting support.
About iVascular
iVascular is a well-established medical device company founded in Barcelona in 2010,
focusing on the development of innovative cardiovascular interventional solutions for the
treatment of cardiac and vascular diseases
